Simultaneous detection of colorectal cancer mutations in stool samples with biochip arrays

Journal of Medical Biochemistry

Volumn 28, Issue 4, 2009, Pages 285-292

  Murray, Helena ^a   Latten, Mark ^a   Cartwright, Andrew ^a   McAleer, Damien ^a   Fitzgerald, Stephen ^a  

^a Randox Laboratories Ltd   (United Kingdom)

Author keywords

Biochip array technology; Colorectal cancer; Mutation; Non invasive; Stool

Indexed keywords

B RAF KINASE; DNA;

ARTICLE; BIOCHIP; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; FECES ANALYSIS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; ONCOGENE K RAS; POLYMERASE CHAIN REACTION;

EID: 70449371304     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-009-0028-5     Document Type: Article

References (38)

1. Preventive Services Task Force. Recommendations and rationale: Screening for colorectal cancer. 2nd ed. Balti - more, Md: Williams and Wilkins; 1996; 89-103.
2. Prix L, Uciechhowski P, Böckmann B, Giesing M, Schuetz AJ. Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clinical Chemistry 2002; 48 (3): 428-435
3. Osborn NK, Ahlquist DA. Stool screening for colore ctal cancer: Molecular approaches. Gastroenterology 2005; 128: 192-206.
4. Fearon ER, Vogelstein B. A genetic model for colo rectal tumourigenesis. Cell 1990; 61: 759-767
5. Levin B, Brooks D, Smith RA, Stone A. Emerging techno - logies in screening for colorectal cancer: CT colo no - graphy, immunochemical faecal occult blood tests, and stool screening using molecular markers. CA: A Cancer Journal for Clinicians 2003; 53: 44-55.
6. Ahlquist, DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clinica Chimica Acta 2002; 315: 157-168
7. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Research 2002; 62: 6451-6455
8. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Can cer Research 1994; 54: 5527-5530
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
10. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Limura K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wildtype with respect to both oncogenes showing different patterns of DNA methylation. Journal of Clinical Oncology 2004; 22 (22): 4584-4594
11. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu, VE. Tumourigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
12. Iacopetta B. TP53 mutation in colorectal cancer. Human Mutation 2003; 21: 271-276
13. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumourigenesis. Cancer Research 1990; 50: 7717-7722
14. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant che motherapy and type of mutation. European Journal of Cancer 2000; 36: 2053-2060
15. Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Human Mutation 2000; 15: 105-113 (Pubitemid 30036177)
16. Soussi T, Beroud C. Significance of p53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. Human Mutation 2003; 21: 192-200.
17. Miyaki M, Konishsi M, Kikuchi-Yanoshita, R, Enomoto, M, Igari T, Tanaka K, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumours. Cancer Research 1994; 54: 3011-3020
18. Miyoshi, Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic mutations of the APC gene in colorectal tumours: Mutation cluster region in the APC gene. Human Molecular Genetics 1992; 1: 229-333.
19. Beroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumours and cell lines. Nucleic Acids Research 1996; 24: 121-124 (Pubitemid 26085747)
20. FitzGerald SP, Lamont JV, McConnell RI, Benchikh EO. Development of a high-throughput automated analyzer using biochip array technology. Clinical Chemistry 2005; 51 (7): 1165-1176
21. Molloy RM, McConnell RI, Lamont JV, FitzGerald SP. Automation of biochip array technology for quality results. Clinical Chemistry Laboratory Medicine 2005; 43 (12): 1303-1313
22. McAleer D, McPhillips FM, FitzGerald SP, McCo n nell RI, Rodriguez ML. Application of evidence investi - gatorTM for the simultaneous measurement of soluble adhesion molecules: L-, P-, E-selectins, VCAM-1, ICAM-1 in a bio chip platform. Journal of Immuno assay and Immuno chemistry 2006; 27 (4): 363-378
23. FitzGerald SP, Piper M, McAleer D, McConnell RI. Application of evidence biochip array technology to drug analysis in sports testing. Proceedings of the 16th International Conference of Racing Analysts and Veterinarians 2006; 412-418
24. FitzGerald SP, McConnell RI, Huxley A. Simultaneous analysis of circulating human cytokines using a highsensitivity cytokine biochip array. Journal of Proteome Research 2008; 7 (1): 450-455
25. Behn M, Qun S, Pankow W, Havemann K, Schuermann M. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based 'enriched PCR' technique. Clinical Cancer Research 1998; 4: 361-371
26. Lüchtenborg M, Weijenberg MP, Roeman GMJM, De Bruïne AP, Van den Brandt PA, Lentjes MHFM, et al. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis 2004; 25: 1219-1226
27. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. Journal of the National Cancer Institute 2001; 93: 858-865
28. Berger BM, Robison BS, Glickman J. Colon cancer-assoc - iated DNA mutations: Marker selection for the detection of proximal colon cancer. Diagnostic Molecular Patho - logy 2003; 12: 187-192
29. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, et al. Molecular detection of tumour cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. Journal of the National Cancer Institute 1999; 91: 332-339
30. Lichenstein AV, Serdjuk OI, Sukhova TI, Melko nyan HS, Uman sky SR. Selective 'stencil'-aided pre-PCR cleavage of wildtype sequences as a novel approach to detection of mutant K-ras. Nucleic Acids Research 2001; 29 (17) e90.
31. Imperiale TF, Ransohoff DF, Itkowitz SH, Turnbull BA, Ross ME. Faecal DNA versus faecal occult blood for colorectal-cancer screening in an average-risk po - pulation. New England Journal of Medicine 2004; 351: 2704-2714
32. Itzowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy III, PC, Sontag S, et al. Improved fecal DNA test for colo - rectal cancer screening. Clinical Gastroenterology and Hepatology 2007; 5: 111-117
33. Kann L, Han J, Ahlquist D, Levin T, Rex D, Whit ney D, et al. Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal cancer. Clinical Chemistry 2006; 52 (12): 2299-2302
34. Itzowitz S, Brand R, Jandorf L, Durkee K, Millhol land J, Rabeneck L, et al. A simplified, non-invasive stool DNA test for colorectal cancer detection. American Journal of Gastroenterology 2008; 103 (11): 2862-2870
35. Ogreid D, Hamre E. Stool DNA analysis detects pre mor - phological colorectal neoplasia: A case report. Euro pean Journal of Gastroenterology & Hepatology 2007; 19 (8): 725-727
36. Bleeker FE, Bardelli A. Genomic landscapes of cancers: prospects for targeted therapies. Pharmacogenomics 2007; 8 (12): 1629-1633
37. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epider mal growth factor receptor antibody therapies. Cancer Research 2007; 67 (6): 2643-2648
38. Lievre A, Bachet JB, le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006; 66 (8): 3992-3995